Real-world data suggest that Erleada may offer an advantage over other treatment options for patients with metastatic ...

Stock image by PDPics from PixabayA Flinders University study shows that bowel cancer survivors face an elevated risk of ...

Data from clinical trials have indicated that PSA is prognostic for outcomes, but little is known about real-world trends.

A new population-level study from Uppsala University has found that most men treated for non-metastatic prostate cancer according to current clinical guidelines have a favorable long-term prognosis.

A large Department of Veterans Affairs cohort study revealed key racial differences in genomic alterations among men with metastatic prostate cancer.

Investigators evaluated the effectiveness of an immunotherapy in combination with standard radiation therapy for patients with intermediate-high risk localized prostate cancer.

Most men who are treated for prostate cancer according to modern guidelines have good survival rates and the majority of these men will die of causes ...

During a live event, Jahan Aghalar, MD, discussed key NCCN-recommended oral therapies and landmark trials for metastatic prostate cancer.

J&J has rights to niraparib in prostate cancer, and views the drug as a successor to Zytiga, once a $2.5 billion-a-year ...

Prostate cancer is the second most common cancer diagnosis in men. About one in eight men will be diagnosed with this disease during their lifetime. New Mexico Living spoke with Dr. Jose Avitia ...